Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

LOS ANGELES--(BUSINESS WIRE)---- $BAYRY #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Bayer Aktiengesellschaft ("Bayer" or the "Company") (OTC: BAYRY) investors concerning the Company and its officers’ possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Announces Investigation of Bayer Aktiengesellschaft (BAYRY) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $BAYRY #INVESTORS--INVESTOR ALERT: Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Bayer Aktiengesellschaft (BAYRY) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $BAYRY #fraud--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Bayer Aktiengesellschaft (BAYRY) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Bayer Aktiengesellschaft (BAYRY) on Behalf of Investors

Veeva Systems

BARCELONA, Spain--(BUSINESS WIRE)--Bayer AG has selected Veeva Vault Study Startup and Veeva Vault eTMF globally to accelerate site activation and improve visibility across trials.

Bayer AG Standardizes on Veeva Vault Clinical Applications Globally

A groundskeeper who used Roundup wins on appeal, collecting $20.4 million, and emboldening other plaintiffs in the weedkiller suits. But new tax rules mean that plaintiffs pay taxes on legal fees they don't even see.

Plaintiff Wins Roundup Weedkiller Appeal But Faces IRS Taxes

CAMBRIDGE, Mass. & BERLIN--(BUSINESS WIRE)--Vesigen Therapeutics launched today with the objective to overcome the hurdle of targeted intracellular drug delivery of next-generation therapeutics, such as CRISPR-cas9, RNA molecules and other therapeutic proteins, by using a proprietary delivery technology.

Vesigen Therapeutics Launches with USD 28.5 Million Series A Investment Led by Leaps by Bayer and Morningside Ventures

MONHEIM, Germany--(BUSINESS WIRE)--Agriculture may now have another solution to positively impact climate change thanks to a new initiative launched by Bayer. Beginning this month, Bayer will start rewarding farmers in Brazil and the U.S.

Bayer takes steps to make carbon sequestration a farmer’s newest crop opportunity

New York, New York--(Newsfile Corp. - July 21, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Bayer Aktiengesellschaft ("Bayer" or the "Company") (OTC Pink: BAYRY) of the September 14, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Bayer Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 In Bayer Aktiengesellschaft To Contact The Firm

LOS ANGELES--(BUSINESS WIRE)---- $BAYRY #BAYRY--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bayer Aktiengesellschaft

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bayer Aktiengesellschaft and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, July 20, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Bayer Aktiengesellschaft (OTC: BAYRY, BAYZF) between May 23, 2016 and March 19, 2019, inclusive (the.

ROSEN, GLOBAL INVESTOR COUNSEL, Announces Filing of Securities Class Action Lawsuit Against Bayer Aktiengesellschaft; Encourages Investors with Losses in Excess of $100K to Contact the Firm - BAYRY, BAYZF

The court said Dewayne Johnson offered "abundant" evidence that glyphosate and other Roundup ingredients caused his cancer.

Chemical company Bayer loses appeal against weedkiller cancer ruling

San Francisco, California--(Newsfile Corp. - July 20, 2020) -  Hagens Berman urges investors in Bayer Aktiengesellschaft (OTC Pink: BAYRY) who suffered $1 million or more in losses to submit their losses now for evaluation by the legal team.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Bayer Aktiengesellschaft (BAYRY) Investors of the Monsanto/Roundup Securities Fraud Class Action Deadline, Encourages Investors With Losses Exceeding $1 Million to Contact Firm

WHIPPANY, N.J.--(BUSINESS WIRE)--For the second consecutive year, Bayer U.S.

Bayer Continues to Earn Top Marks in 2020 Disability Equality Index

NEW ORLEANS, July 17, 2020 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 14, 2020 to file lead plaintiff applications in a securities class action lawsuit against.

BAYER SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bayer Aktiengesellschaft - BAYRY

New York, New York--(Newsfile Corp. - July 17, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Bayer Aktiengesellschaft ("Bayer" or the "Company") (OTC: BAYRY, BAYZF) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired PlayAGS securities between May 23, 2016 and March 19, 2019, both dates inclusive (the "Class Period").

BAYRY SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Bayer Aktiengesellschaft Shareholders With Losses Exceeding $1.9 Million of Class Action and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $BAYRY #BAYRY--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bayer Aktiengesellschaft

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Bayer Aktiengesellschaft and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Bayer Aktiengesellschaft (OTC: BAYRY, BAYZF) between May 23, 2016 and March 19, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Bayer investors under the federal securities laws.

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Bayer Aktiengesellschaft – BAYRY, BAYZF

NEW YORK, July 15, 2020 /PRNewswire/ -- Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action lawsuit for violations of the federal securities laws in the U.S. District Court for the Northern District of California against Bayer.

Shareholder Alert: Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of a Securities Class Action Lawsuit Against Bayer Aktiengesellschaft

Elanco Animal Health Inc

Elanco Animal Health Inc has decided against acquiring Bayer AG's Canadian distribution rights to several poultry insecticides, Canada's Competition Bureau said on Tuesday, as it looks to complete a $7.6-billion deal.

Elanco to divest brands, forgo Canadian rights for Bayer's unit deal

Bayer's (BAYRY) investigational candidate, finerenone, meets primary endpoint in the phase III FIDELIO_DKD study in patients with CKD and T2D.

Bayer's Drug Meets Primary Endpoint in Renal Outcomes Study

Bayer has agreed to delay part of a proposed settlement of allegations that its widely used weedkiller Roundup caused cancer after a U.S. judge questioned its plan to deal with future claims.

Bayer puts part of Roundup settlement on hold

Bayer shares dropped 6% on Tuesday after a U.S. judge questioned the German company's proposed settlement to deal with future claims relating to allegations that its widely-used weedkiller Roundup caused cancer.

Bayer shares tumble after judge questions part of Roundup settlement

There is a major drama playing out in farm country involving glyphosate, the broad-spectrum systemic herbicide and crop desiccant.

Bayer To Pay More Than $10 Billion In Roundup Settlement

Bayer AG (OTC: BAYRY) will pay between $10.1 to $10.9 billion to resolve litigation over the weedkiller Roundup.

Bayer Settles Most Cases Related To Roundup Herbicide For Up To $10.9B

Seeking to forestall further claims, Bayer AG is taking a risky bet that an independent scientific review will ultimately show that its widely used weed killer Roundup does not cause cancer, legal experts said.

News for Bayer AG Stock (BAYRY)